Skip to content
PeptidesAsiaPeptide Library
Peptide care, guided by a doctor.Explore treatments

In context

Degarelix is the active ingredient in Firmagon, with a label for advanced prostate cancer. [1]

Editorial basisLinked primary sources
Source checked2026-11-07
Clinical reviewNo named medical review

At a glance

Type
Medicine / medicine family
Regulatory context
United States: this overview describes the cited product-specific prescribing information. It is not a statement of Thai approval or current commercial availability.
Evidence
The cited product label defines a clinical indication and its limits. It does not validate every formulation or use of a related molecule.

Scope of the labelled use

Suppression of hormone signalling in cancer care should not be confused with routine hormone optimisation. [1]

Formulation and jurisdiction

A medicine label applies to its named formulation and clinical use. Approval of one product does not establish equivalence for compounded preparations or products bought as research materials. [1]

Safety and clinical context

The full prescribing information includes product-specific warnings, contraindications and monitoring requirements. A clinical assessment must consider these alongside other medicines and individual health conditions.

Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.

Primary sources

Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.

  1. FIRMAGON — US prescribing information dailymed.nlm.nih.gov

How we use evidence and describe review

Popular peptides

Explore by body region